MilliporeSigma
Search Within

CLL1141

Applied Filters:
Keyword:'CLL1141'
Showing 1-8 of 8 results for "CLL1141" within Papers
Kenji Tanabe
Scientific reports, 6, 25095-25095 (2016-04-28)
Small-molecule compounds are widely used as biological research tools and therapeutic drugs. Therefore, uncovering novel targets of these compounds should provide insights that are valuable in both basic and clinical studies. I developed a method for image-based compound profiling by
A chromosomal region 7p11.2 transcript map: its development and application to the study of EGFR amplicons in glioblastoma.
Eley GD
Neuro-Oncology, 4(2), 86-94 (2002)
Kenji Tanabe et al.
SLAS discovery : advancing life sciences R & D, 23(4), 330-340 (2018-01-04)
A major advantage of image-based phenotypic profiling of compounds is that numerous image features can be sampled and quantitatively evaluated in an unbiased way. However, since this assay is a discovery-oriented screening, it is difficult to determine the optimal experimental
Effect of epidermal growth factor receptor gene polymorphisms on prognosis in glioma patients.
Li B, et al.
Oncotarget, 7(39), 63054-63054 (2016)
Catarina Oliveira Silva et al.
PloS one, 11(10), e0165419-e0165419 (2016-10-28)
The application of functionalized nanocarriers on photothermal therapy for cancer ablation has wide interest. The success of this application depends on the therapeutic efficiency and biocompatibility of the system, but also on the stability and biorecognition of the conjugated protein.
Cláudia M Botelho et al.
Journal of biophotonics, 11(9), e201700323-e201700323 (2018-03-15)
Epidermal growth factor receptor (EGFR) plays a key role in regulating cell survival, proliferation and migration, and its overexpression and activation has been correlated with cancer progression. Cancer therapies targeting EGFR have been applied in the clinic with some success.
Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications (2015)
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.
Brand TM
Cancer Biology & Therapy, 11(9), 777-792 (2011)
Page 1 of 1